Gut microbiota and inflammation

Nutrients

Volumn 3, Issue 6, 2011, Pages 637-687

  Hakansson, Asa ^a   Molin, Goran ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Gut Microbiota; Inflammation; Probiotics

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PROBIOTIC AGENT; RNA 16S; TUMOR NECROSIS FACTOR ALPHA; VSL3;

ACTINOBACTERIA; ALCOHOL LIVER CIRRHOSIS; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; ATOPY; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BACTEROIDETES; COLORECTAL CANCER; CROHN DISEASE; FIRMICUTES; FUSOBACTERIA; GASTROINTESTINAL TRACT FUNCTION; GENE SEQUENCE; GENOTYPE; HEPATIC ENCEPHALOPATHY; HUMAN; ILEITIS; IMMUNOMODULATION; INFLAMMATION; INTESTINE FLORA; INTESTINE INJURY; LIVER CIRRHOSIS; LIVER FIBROSIS; METABOLIC SYNDROME X; MOUTH FLORA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHENOTYPE; PROTEOBACTERIA; RADIATION ENTEROPATHY; REGULATORY T LYMPHOCYTE; REVIEW; SPIROCHAETA; ULCERATIVE COLITIS;

ANIMALIA;

EID: 79959861780     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu3060637     Document Type: Review

References (240)

1. Mölne, J.; Wold, A. Inflammation, 1st ed.; Liber AB: Stockholm, Sweden, 2007.
2. Pepys, M.B.; Baltz, M.L. Acute phase proteins with special reference to C-reactive and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 1983, 34, 141-212.
3. Ridker, P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107, 363-369.
4. Piéroni, L.; Bastard, J.P.; Piton, A.; Khalil, L.; Hainque, B.; Jardel, C. Interpretation of circulating C-reactive protein levels in adults: Body mass index and gender are a must. Diabetes Metab. 2003, 29, 133-138.
5. Visser, M.; Bouter, L.M.; McQuillan, G.M.; Wener, M.H.; Harris, T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282, 2131-2135.
6. Rescigno, M.; Urbano, M.; Valzasina, B.; Francolini, M.; Rotta, G.; Bonasio, R.; Granucci, F.; Kraehenbuhl, J.P.; Ricciardi-Castagnoli, P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2, 361-367.
7. Newberry, R.D.; Lorenz, R.G. Organizing a mucosal defence. Immunol. Rev. 2005, 206, 6-21.
8. Forchielli, M.L.; Walker, W.A. The role of gut-associated lymphoid tissues and mucosal defence. Br. J. Nutr. 2005, 93, S41-S48.
9. Izcue, A.; Coombes, J.L.; Powrie, F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 2009, 27, 313-338.
10. Palmblad, J. The role of granulocytes in inflammation. Scand. J. Rheumatol. 1984, 13, 163-172.
11. Fujiwara, N.; Kobayashi, K. Macrophages in inflammation. Curr. Drug Targets Inflamm. Allergy 2005, 4, 281-286.
12. Van Ginderachter, J.A.; Movahedi, K.; Ghassabeh, G.H.; Meerschaut, S.; Beschin, A.; Raes, G.; De Baetselier, P. Classical and alternative activation of mononuclear phagocytes: Picking the best of both worlds for tumor promotion. Immunobiology 2006, 211, 487-501.
13. Anderson, C.F.; Mosser, D.M. A novel phenotype for an activated macrophage: The type 2 activated macrophage. J. Leukoc. Biol. 2002, 72, 101-106.
14. Gordon, S. Alternative activation of macrophages. Nat. Rev. 2003, 3, 23-35.
15. Mosser, D.M. The many faces of macrophage activation. J. Leukoc. Biol. 2003, 73, 209-212.
16. Umesaki, Y.; Setoyama, H.; Matsumoto, S.; Okada, Y. Expansion of alpha beta T cell receptor-bearing intestinal intraepithelial lymphocytes after microbial colonization in germ-free mice and its independence from thymus. Immunology 1993, 79, 32-37.
17. Helgeland, L.; Vaage, J.T.; Rolstad, B.; Midtvedt, T.; Brandtzaeg, P. Microbial colonization influences composition and T cell receptor V beta repertoire of intraepithelial lymphocytes in rat intestine. Immunology 1996, 89, 494-501.
18. Cebra, J.J.; Periwal, S.B.; Lee, G.; Lee, F.; Shroff, K.E. Development and maintenance of the gut-associated lymphoid tissue (GALT): The roles of enteric bacteria and viruses. Dev. Immunol. 1998, 6, 13-18.
19. Butler, J.E.; Sun, J.; Weber, P.; Navarro, P.; Francis, D. Antibody repertoire development in fetal and newborn piglets, III. Colonization of the gastrointestinal tract selectively diversifies the preimmune repertoire in mucosal lymphoid tissues. Immunology 2000, 100, 119-130.
20. Cario, E.; Brown, D.; McKee, M.; Lynch-Devaney, K.; Gerken, G.; Podolsky, D.K. Commensal associated molecular patterns induce selective toll-like receptor-trafficking from apical membrane to cytoplasmic compartments in polarized intestinal epithelium. Am. J. Pathol. 2002, 160, 165-173.
21. Hershberg, R.M.; Mayer, L.F. Antigen processing and presentation by intestinal epithelial cells-polarity and complexity. Immunol. Today 2000, 21, 123-128.
22. Testro, A.G.; Visvanathan, K. Toll-like receptors and their role in gastrointestinal disease. J. Gastroenterol. Hepatol. 2009, 24, 943-954.
23. Zarember, K.A.; Godowski, P.J. Tissue expression of human Tolllike receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168, 554-561.
24. Fichorova, R.N.; Cronin, A.O.; Lien, E.; Anderson, D.J.; Ingalls, R.R. Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signalling. J. Immunol. 2002, 168, 2424-2432.
25. Poltorak, A.; He, X.; Smirnova, I.; Liu, M.Y.; Van Huffel, C.; Du, X.; Birdwell, D.; Alejos, E.; Silva, M.; Galanos, C. et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998, 282, 2085-2088.
26. Qureshi, S.T.; Lariviere, L.; Leveque, G.; Clermont, S.; Moore, K.J.; Gros, P.; Malo, D. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 1999, 189, 615-625.
27. Schwandner, R.; Dziarski, R.; Wesche, H.; Rothe, M.; Kirschning, C.J. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll-like receptor 2. J. Biol. Chem. 1999, 274, 17406-17409.
28. Takeuchi, O.; Kaufmann, A.; Grote, K.; Kawai, T.; Hoshino, K.; Morr, M.; Mühlradt, P.F.; Akira, S. Cutting edge: Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 2000, 164, 554-557.
29. Philpott, D.J.; Girardin, S.E.; Sansonetti, P.J. Innate immune responses of epithelial cells following infection with bacterial pathogens. Curr. Opin. Immunol. 2001, 13, 410-416.
30. Girardin, S.E.; Tournebize, R.; Mavris, M.; Page, A.L.; Li, X.; Stark, G.R.; Bertin, J.; DiStefano, P.S.; Yaniv, M.; Sansonetti, P.J. et al. CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep. 2001, 2, 736-742.
31. Girardin, S.E.; Boneca, I.G.; Carneiro, L.A.; Antignac, A.; Jéhanno, M.; Viala, J.; Tedin, K.; Taha, M.K.; Labigne, A.; Zähringer, U. et al. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 2003, 300, 1584-1587.
32. Hasegawa, M.; Yang, K.; Hashimoto, M.; Park, J.H.; Kim, Y.G.; Fujimoto, Y.; Nuñez, G.; Fukase, K.; Inohara, N. Differential release and distribution of Nod1 and Nod2 immunostimulatory molecules among bacterial species and environments. J. Biol. Chem. 2006, 281, 29054-29063.
33. Chen, G.; Shaw, M.H.; Kim, Y.G.; Nunez, G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu. Rev. Pathol. Mech. Dis. 2009, 4, 365-398.
34. Pickard, K.M.; Bremner, A.R.; Gordon, J.N.; MacDonald, T.T. Microbial gut interactions in health and disease. Immune responses. Best Pract. Res. Clin. Gastroenterol. 2004, 18, 271&.
35. Cheroutre, H. Starting at the beginning: new perspectives on the biology of mucosal T cells. Annu. Rev. Immunol. 2004, 22, 217-246.
36. Cash, H.L.; Whitham, C.V.; Behrendt, C.L.; Hooper, L.V. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006, 313, 1126-1130.
37. Cerutti, A.; Rescigno, M. The biology of intestinal immunoglobulin A responses. Immunity 2008, 28, 740-750.
38. Eisen, J.A. Environmental shotgun sequencing: Its potential and challenges for studying the hidden world of microbes. PLoS Biol. 2007, 5, e82.
39. Handelsman, J.; Rondon, M.R.; Brady, S.F.; Clardy, J.; Goodman, R.M. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. 1998, 5, 245-249.
40. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464, 59-65.
41. Tap, J.; Mondot, S.; Levenez, F.; Pelletier, E.; Caron, C.; Furet, J.P.; Ugarte, E.; Muñoz-Tamayo, R.; Paslier, D.L.E.; Nalin, R. et al. Towards the human intestinal microbiota phylogenetic core. Environ. Microbiol. 2009, 11, 2574-2584.
42. Costello, E.K.; Lauber, C.L.; Hamady, C.; Fierer, N.; Gordon, J.I.; Knight, R. Bacterial community variation in human body habitats across space and time. Science 2009, 326, 1694-1697.
43. Wang, M.; Ahrné, S.; Jeppsson, B.; Molin, G. Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. FEMS Microbiol. Ecol. 2005, 54, 219-231.
44. Cheng, K.J.; Costerton, J.W. Ultrastructure of Butyrivibrio fibrisolvens: A gram-positive bacterium? J. Bacteriol. 1977, 129, 1506-1512.
45. Pettersson, B.; Ahrné, S.; Wang, M.; Jeppsson, B.; Uhlén, M.; Molin, G. The Mucosa-Associated Bacteria from the Sigmoid Colon of Nine Healthy 60-Year-Old Individuals, Identified by Bacterial 16S rDNA; Lund University Publications (LUP, Lund): Lund, Sweden, 2003.
46. Hayashi, H.; Takahashi, R.; Nishi, T.; Sakamoto, M.; Benno, Y. Molecular analysis of jejunal, ileal, caecal and rectosigmoidal human colonic microbiota using 16S rRNA gene libraries and terminal restriction fragment length polymorphism. J. Med. Microbiol. 2005, 54, 1093-1101.
47. Bik, E.M.; Eckburg, P.B.; Gill, S.R.; Nelson, K.E.; Purdom, E.A.; Francois, F.; Perez-Perez, G.; Blaser, M.J.; Relman, D.A. Molecular Analysis of the Bacterial Microbiota in the Human Stomach. Proc. Natl. Acad. Sci. USA 2006, 103, 732-737.
48. Lazarevic, V.; Whiteson, K.; Huse, S.; Hernandez, D.; Farinelli, L.; Østerås, M.; Schrenzel, J.; François, P. Metagenomic study of the oral microbiota by Illumina high-throughput sequencing. J. Microbiol. Methods 2009, 79, 266-271.
49. Li, X.X.; Wong, G.L.H.; To, K.F.; Wong, V.W.S.; Lai, L.H.; Chow, D.K.L.; Lau, J.U.W.; Sung, J.J.Y.; Ding, C. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One 2009, 4, e7985.
50. Nasidze, I.; Li, J.; Quinque, D.; Tang, K.; Stoneking, M. Global diversity in the human salivary microbiome. Genome Res. 2009, 19, 636-643.
51. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J.P. et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480-484.
52. Rheims, H.; Sproer, C.; Rainey, F.A.; Stackebrandt, E. Molecular biological evidence for the occurrence of uncultured members of the actinomycete line of descent in different environments and geographical locations. Microbiology 1996, 142, 2863-2870.
53. Huyghe, A.; Francois, P.; Charbonnier, Y.; Tangomo-Bento, M.; Bonetti, E.J.; Paster, B.J.; Bolivar, I.; Baratti-Mayer, D.; Pittet, D.; Schrenzel, J. Novel microarray design strategy to study complex bacterial communities. Appl. Environ. Microbiol. 2008, 74, 1876-1885.
54. Collins, M.D.; Lawson, P.A.; Willems, A.; Cordoba, J.J.; Fernandez-Garayzabal, J.; Garcia, P.; Cai, J.; Hippe, H.; Farrow, J.A. The phylogeny of the genus Clostridium: Proposal of five new genera and eleven new species combinations. Int. J. Syst. Bacteriol. 1994, 44, 812-826.
55. Hold, G.L.; Pryde, S.E.; Russell, V.J.; Furrie, E.; Flint, H.J. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. FEMS Microbiol. Ecol. 2002, 39, 33-39.
56. Zhang, H.; DiBaise, J.K.; Zuccolo, A.; Kudrna, D.; Braidotti, M.; Yu, Y.; Parameswaran, P.; Crowell, M.D.; Wing, R.; Rittmann, B.E. et al. Human gut microbiota in obesity and after gastric bypass. PNAS 2009, 106, 2365-2370.
57. Friedrich, M.J. Microbiome project seeks to understand human body's microscopic residents. JAMA 2008, 300, 777-778.
58. Kleessen, B.; Kroesen, A.J.; Buhr, H.J.; Blaut, M.; Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. 2002, 37, 1034-1041.
59. Swidsinski, A.; Weber, J.; Loening-Baucke, V.; Hale, L.P.; Lochs, H.; Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 2005, 43, 3380-3389.
60. Wang, M.; Molin, G.; Ahrné, S.; Adawi, D.; Jeppsson, B. High proportions of proinflammatory bacteria on the colonic mucosa in a young patient with ulcerative colitis as revealed by cloning and sequencing of 16S rRNA genes. Dig. Dis. Sci. 2007, 52, 620-627.
61. Gangloff, S.C.; Hijiya, N.; Haziot, A.; Goyert, S.M. Lipopolysaccharide structure influences the macrophage response via CD14-independent and CD14-dependent pathways. Clin. Infect. Dis. 1999, 28, 491-496.
62. Lindberg, A.A.; Weintraub, A.; Zahringer, U.; Rietschel, E.T. Structure-activity relationships in lipopolysaccharides of Bacteroides fragilis. Rev. Infect. Dis. 1990, 12, S133-S141.
63. Poxton, I.R.; Edmond, D.M. Biological activity of Bacteroides lipopolysaccharide-reappraisal. Clin. Infect. Dis. 1995, 20, S149-S153.
64. Berezowa, A.B.; Ernst R.K.; Coats, S.R.; Brahamc, P.H.; Karimi-Naser, L.M.; Darveau, R.P. The structurally similar, penta-acylated lipopolysaccharides of Porphyromonas gingivalis and Bacteroides elicit strikingly different innate immune responses. Microb. Pathog. 2009, 47, 68-77.
65. Kasper, D.L.; Hayes, M.E.; Reinap, B.G.; Craft, F.O.; Onderdonk, A.B.; Polk, B.F.; Isolation and identification of encapsulated strains of Bacteroides fragilis. J. Infect. Dis. 1977, 136, 75-81.
66. Cani, P.D.; Amar, J.; Iglesias, M.A.; Poggi, M.; Knauf, C.; Bastelica, D.; Neyrinck, A.M.; Fava, F.; Tuohy, K.M.; Chabo, C. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56, 1761-1772.
67. Cani, P.D.; Bibiloni, R.; Knauf, C.; Waget, A.; Neyrinck, A.M.; Delzenne, N.M.; Burcelin, R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57, 1470-1481.
68. González-Navajas J.M.; Bellot, P.; Francés, R.; Zapater, P.; Munoz, C.; García-Pagán, J.C.; Pascual, S.; Pérez-Mateo, M.; Bosch, J.; Such, J.; Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J. Hepatol. 2008, 48, 61-67.
69. Biagi, B.; Nylund, L.; Candela, M.; Ostan, R.; Bucci, L.; Pini, E.; Nikkila, J.; Monti, D.; Satokari, R.; Franceschi, C. et al. Through ageing, and beyond: Gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010, 5, e10667.
70. Onderdonk, A.B. Animal models simulating anaerobic infections. Anaerobe 2005, 11, 189-195.
71. Onderdonk, A.B.; Bartlett, J.G.; Louie, T.; Sullivan-Seigler, N.; Gorbach, S.L.; Microbial synergy in experimental intra-abdominal abscess. Infect.Immun. 1976, 13, 22-26.
72. Kim, J.M.; Kim, Y.J.; Cho, Y.J.; Synergy of Bacteroides fragilis and Escherichia coli in the induction of KC gene expression in mouse peritoneal tissues. Scand. J. Infect. Dis. 2000, 32, 643-649.
73. Rotstein, O.D.; Vittorini, T.; Kao, J.; McBurney, I.; Nasmith, P.; Grinstein, S.A. A soluble Bacteroides by-product impairs phagocytic killing of Escherichia coli by neutrophils. Infect. Immun. 1989, 57, 745-753.
74. Montravers, P.; Mohler, J.; Saint Julien, L.; Carbon, C. Evidence of the proinflammatory role of Enterococcus faecalis in polymicrobial peritonitis in rats. Infect.Immun. 1997, 65, 144-149.
75. Magnuson, D.K.; Weintraub, A.; Pohlman, H.; Maier, R.V. Human endothelial cell adhesiveness of neutrophils, induced by Escherichia coli lipopolysaccharide in vitro, is inhibited by Bacteroides fragilis lipopolysaccharide. J. Immunol. 1989, 143, 3025-3030.
76. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermudez-Humara, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. PNAS 2008, 105, 16731-16736.
77. Forsythe, P.; Bienenstock, J.; Immunomodulation by commensal and probiotic bacteria. Immunol.Invest. 2010, 39, 429-448.
78. Lilley, D.M.; Stillwell, R.H. Probiotics: Growth promoting factors produced by microorganisms. Science 1965, 147, 747-748.
79. FAO/WHO. Guidelines for the Evaluation of Probiotics in Food; Joint FAO/WHO Working Group Report, London, Ontario, Canada, April 30 and May 1, 2002; WHO: Geneva, Switzerland, 2002.
80. Metchnikoff, E.; The Prolongation of Life; Heinemann: London, UK, 1907.
81. Vásquez, A.; Molin, G.; Pettersson, B.; Antonsson, M.; Ahrné, S. DNA-based classification and sequence heterogeneities in the 16S rRNA genes of Lactobacillus casei/paracasei and related species. Syst. Appl. Microbiol. 2005, 28, 430-441.
82. Besselink, M.G.H.; van Santvoort, H.C.; Buskens, E.; Boermeester, M.A.; van Goor, H.; Timmerman, H.M.; Nieuwenhuijs, V.B.; Bollen, T.L.; van Ramshorst, B.; Witteman, B.J.M. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: A randomised, double-blind, placebo-controlled trial. Lancet 2008, 371, 651-659.
83. Qin, H.L.; Zheng, J.J.; Tong, D.N.; Chen, W.X.; Fan, X.B.; Hang, X.M.; Jiang, Y.Q.; Effect of Lactobacillus plantarum enteral feeding on the gut permeability and septic complications in the patients with acute pancreatitis. Eur. J. Clin. Nutr. 2008, 62, 923-930.
84. Sierra, S.; Lara-Villoslada, F.; Sempere, L.; Olivares, M.; Boza, J.; Xaus, J. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe 2010, 16, 195-200.
85. Takeda, K.; Suzuki, T.; Shimada, S.I.; Shida, K.; Nanno, M.; Okumura, K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clin.Exp.Immunol. 2006, 146, 109-115.
86. Roessler, A.; Friedrich, U.; Vogelsang, H.; Bauer, A.; Kaatz, M.; Hipler, U.C.; Schmidt, I.; Jahreis, G.; The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin.Exp.Allergy 2008, 38, 93-102.
87. Klein, A.; Friedrich, U.; Vogelsang, H.; Jahreis, G.; Lactobacillus acidophilus 74-2 and Bifidobacterium animalis subsp. lactis DGCC 420 modulate unspecific cellular immune response in healthy adults. Eur. J. Clin. Nutr. 2008, 62, 584-593.
88. Pelto, L.; Isolauri, E.; Lilius, E.M.; Nuutila, J.; Salminen, S. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin.Exp.Allergy 1998, 28, 1474-1479.
89. Karczewski, J.; Troost, F.J.; Konings, I.; Dekker, J.; Kleerebezem, M.; Brummer, R.J.M.; Wells, J.M.; Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G851-G859.
90. Kiessling, G.; Schneider, J.; Jahreis, G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. Eur. J. Clin. Nutr. 2002, 56, 843-849.
91. Hata, Y.; Yamamoto, M.; Ohni, M.; Nakajima, K.; Nakamura, Y.; Takano, T. A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive. Am. J. Clin. Nutr. 1996, 64, 767-771.
92. Bukowska, H.; Pieczul-Mróz, J.; Jastrzebsk, K.; Chelstowski, K.; Naruszewicz, M. Significant decrease in fibrinogen and LDL-cholesterol levels upon supplementation of the diet with Lactobacillus plantarum (ProViva) in subjects with moderately elevated cholesterol concentrations. Atherosclerosis 1998, 137, 437-438.
93. Naruszewicz, M.; Johansson, M.L.; Zapolska-Downar, D.; Bukowska, H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am. J. Clin. Nutr. 2002, 76, 1249-1255.
94. Gill, H.S.; Rutherfurd, K.J.; Cross, M.L.; Gopal, P.K. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am. J. Clin. Nutr. 2001, 74, 833-839.
95. Loguercio, C.; De Simone, T.; Federico, A.; Terracciano, F.; Tuccillo, C.; Di Chicco, M.; Cartenì, M. Gut-liver axis: A new point of attack to treat chronic liver damage? Am. J. Gastroenterol. 2002, 97, 2144-2146.
96. Loguercio, C.; Federico, A.; Tuccillo, C.; Terracciano, F.; D'Auria, M.V.; De Simone, C.; Del Vecchio Blanco, C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J. Clin. Gastroenterol. 2005, 39, 540-543.
97. Kirpich, I.A.; Solovieva, N.V.; Leikhter, S.N.; Shidakova, N.A.; Lebedeva, O.V.; Sidorov, P.I.; Bazhukova, T.A.; Soloviev, A.G.; Barve, S.S.; McClain, C.J.; et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: A pilot study. Alcohol 2008, 42, 675-682.
98. Stadlbauer, V.; Mookerjee, R.P.; Hodges, S.; Wright, G.A.K.; Davies, N.A.; Jalan, R.; Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J. Hepatol. 2008, 48, 945-951.
99. Liu, Q.; Duan, Z.P.; Ha, D.K.; Bengmark, S.; Kurtovic, J.; Riordan, S.M. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39, 1441-1449.
100. Macbeth, W.A.; Kass, E.H.; McDermott, W.V., Jr. Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus. Lancet 1965, 1, 399-403.
101. Read, A.E.; McCarthy, C.F.; Heaton, K.W.; Laidlaw, J. Lactobacillus acidophilus (Enpac) in treatment of hepatic encephalopathy. BMJ 1966, 1, 1267-1269.
102. Bajaj, J.S.; Saeian, K.; Christensen, K.M.; Hafeezullah, M.; Varma, R.R.; Franco, J.; Pleuss, J.A.; Krakower, G.; Hoffmann, R.G.; Binion, D.G. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am. J. Gastroenterol. 2008, 103, 1707-1715.
103. Rayes, N.; Seehofer, D.; Hansen, S.; Boucsein, K.; Müller, A.R.; Serke, S.; Bengmark, S.; Neuhaus, P.; Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: A controlled trial in liver transplant recipients. Transplantation 2002, 74, 123-127.
104. Rayes, N.; Seehofer, D.; Theruvath, T.; Schiller, R.A.; Langrehr, J.M.; Jonas, S.; Bengmark, S.; Neuhaus, P.; Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation-a randomized, double-blind trial. Am. J. Transplant. 2005, 5, 125-130.
105. McNaught, C.E.; Woodcook, N.P.; Andersson, A.D.G.; MacFie, J. A prospective randomized trial of probiotics in critically ill patients. Clin.Nutr. 2005, 24, 211-219.
106. Klarin, B.; Wullt, M.; Palmquist, I.; Molin, G.; Larsson, A.; Jeppsson, B. Lactobacillus plantarum 299v reduces colonization of Clostridium difficile in critically ill patients treated with antibiotics. Acta Anaesthesiol.Scand. 2008, 52, 1096-1102.
107. Alberda, C.; Gramlich, L.; Meddings, J.; Field, C.; McCargar, L.; Kutsogiannis, D.; Fedorak, R.; Madsen, K. Effects of probiotic therapy in critically ill patients: A randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 2007, 85, 816-823.
108. Taylor, A.L.; Hale, J.; Hales, B.J.; Dunstan, J.A.; Thomas, W.R.; Prescott, S.L. FOXP3 mRNA expression at 6 months of age is higher in infants who develop atopic dermatitis, but is not affected by giving probiotics from birth. Pediatr.Allergy Immunol. 2007, 18, 10-19.
109. Kalliomäki, M.; Salminen, S.; Arvilommi, H.; Kero, P.; Koskinen, P.; Isolauri, E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001, 357, 1076-1079.
110. Isolauri, E.; Arvola, T.; Sütas, Y.; Moilanen, E.; Salminen, S. Probiotics in the management of atopic eczema. Clin.Exp.Allergy 2000, 30, 1604-1610.
111. Ouwehand, A.C.; Nermes, M.; Collado, M.C.; Rautonen, N.; Salminen, S.; Isolauri, E. Specific probiotics alleviate allergic rhinitis during the birch pollen season. WorldJ.Gastroenterol. 2009, 15, 3261-3268.
112. Viljanen, M.; Kuitunen, M.; Haahtela, T.; Juntunen-Backman, K.; Korpela, R.; Savilahti, E.; Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants. Pediatr. Allergy Immunol. 2005, 16, 65-71.
113. Martínez-Cañavate, A.; Sierra, S.; Lara-Villoslada, F.; Romero, J.; Maldonado, J.; Boza, J.; Xaus, J.; Olivares, M.; A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy. Pediatr. Allergy Immunol. 2009, 20, 592-600.
114. Mohan, R.; Koebnick, C.; Schildt, J.; Mueller, M.; Radke, M.; Blaut, M.; Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants.Pediatr. Res. 2008, 64, 418-422.
115. Schultz, M.; Timmer, A.; Herfarth, H.H.; Sartor, R.B.; Vanderhoof, J.A.; Rath, H.C. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004, 4, 5.
116. Bousvaros, A.; Guandalini, S.; Baldassano, R.N.; Botelho, C.; Evans, J.; Ferry, G.D.; Goldin, B.; Hartigan, L.; Kugathasan, S.; Levy, J. et al.; A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 2005, 11, 833-839.
117. Prantera, C.; Scribano, M.L.; Falasco, G.; Andreoli, A.; Luzi, C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002, 51, 405-409.
118. Guandalini, S.; Use of Lactobacillus-GG in paediatric Crohn's disease. Dig. Liver Dis. 2002, 34, S63-S65.
119. Gupta, P.; Andrew, H.; Kirschne, B.S.; Guandalini, S. Is Lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J. Pediatr. Gastroenterol. Nutr. 2000, 31, 453-457.
120. Marteau, P.; Lemann, M.; Seksik, P.; Laharie, D.; Colombei, J.F.; Bouhnik, Y.; Cadiot, G.; Soulé, J.C.; Bourreille, A.; Metman, E. et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55, 842-847.
121. Van Gossum, A.; Dewit, O.; Louis, E.; de Hertogh, G.; Baert, F.; Fontaine, F.; DeVos, M.; Enslen, M.; Paintin, M.; Franchimont, D.; Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm. Bowel Dis. 2007, 13, 135-142.
122. Pronio, A.; Montesani, C.; Butteroni, C.; Vecchione, S.; Mumolo, G.; Vestri, A.; Vitolo, D.; Boirivant, M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm. Bowel Dis. 2008, 14, 662-668.
123. Sood, A.; Midha, V.; Makharia, G.K.; Ahuja, V.; Singal, D.; Goswami, P.; Tandon, R.K. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 2009, 7, 1202-1209.
124. Bibiloni, R.; Fedorak, R.N.; Tannock, G.W.; Madsen, K.L.; Gionchetti, P.; Campieri, M.; De Simone, C.; Sartor, R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 2005, 100, 1539-1546.
125. Gionchetti, P.; Rizzell, F.; Morselli, C.; Poggioli, G.; Tambasco, R.; Calabrese, C.; Brigidi, P.; Vitali, B.; Straforini, G.; Campieri, M. High-dose probiotics for the treatment of active pouchitis. Dis. Colon Rectum 2007, 50, 2075-2082.
126. Tsuda, Y.; Yoshimatsu, Y.; Aoki, H.; Nakamura, K.; Irie, M.; Fukuda, K.; Hosoe, N.; Takada, N.; Shirai, K.; Suzuki, Y. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand. J. Gastroenterol. 2007, 42, 1306-1311.
127. Matthes, H.; Krummenerl, T.; Giensch, M.; Wolff, C.; Schulze, J. Clinical trial: Probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement. Altern. Med. 2010, 10, 13.
128. Lorea Baroja, M.; Kirjavainen, P.V.; Hekmat, S.; Reid, G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin. Exp. Immunol. 2007, 149, 470-479.
129. Zocco, M.A.; dal Verme, L.Z.; Cremonini, F.; Piscaglia, A.C.; Nista, E.C.; Candelli, M.; Novi, M.; Rigante, D.; Cazzato, I.A.; Ojetti, V. et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 2006, 23, 1567-1574.
130. Kato, K.; Mizuno, S.; Umesaki, Y.; Ishii, Y.; Sugitani, M.; Imaoka, A.; Otsuka, M.; Hasunuma, O.; Kurihara, R.; Iwasaki, A. et al.; Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. 2004, 20, 1133-1141.
131. Cui, H.H.; Chen, C.L.; Wang, J.D.; Yang, Y.J.; Cun, Y.; Wu, J.B.; Liu, Y.H.; Dan, H.L.; Jian, Y.T.; Chen, X.Q. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J. Gastroenterol. 2004, 10, 1521-1525.
132. Zhang, J.W.; Du, P.; Chen, D.W.; Cui, L.; Ying, C.M. Effect of viable Bifidobacterium supplement on the immune status and inflammatory response in patients undergoing resection for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2010, 13, 40-43 (in Chinese).
133. Delia, P.; Sansotta, G.; Donato, V.; Frosina, P.; Messina, G.; De Renzis, C.; Famularo, G. Use of probiotics for prevention of radiation-induced diarrhea. World J. Gastroenterol. 2007, 13, 912-915.
134. Urbancsek, H.; Kazar, T.; Mezes, I.; Neumann, K.; Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus in patients with radiation-induced diarrhoea. Eur. J. Gastroenterol. Hepatol. 2001, 13, 391-396.
135. Osterlund, P.; Ruotsalainen, T.; Korpela, R.; Saxelin, M.; Ollus, A.; Valta, P.; Kour, M.; Elomaa, I.; Joensuu, H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: A randomised study. Br. J. Cancer 2007, 97, 1028-1034.
136. Salminen, E.; Elomaa, I.; Minkkinen, J.; Vapaatalo, H.; Salminen, S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin. Radiol. 1988, 39, 435-437.
137. Giralt, J.; Regadera, J.P.; Verges, R.; Romero, J.; de la Fuente, I.; Biete, A.; Villoria, J.; Cobo, J.M.; Guarner, F. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71, 1213-1219.
138. Pandolfi, F.; Cianci, R.; Pagliari, D.; Landolfi, R.; Cammarota, G. Cellular mediators of inflammation: Tregs and TH17 cells in gastrointestinal diseases. Mediators Inflamm. 2009, 2009, 13 2028.
139. Tang, Q.; Bluestone, J.A. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat. Immunol. 2008, 9, 239-244.
140. Baecher-Allan, C.; Brown, J.A.; Freeman, G.J.; Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J. Immunol. 2001, 167, 1245-1253.
141. Maul, J.; Loddenkemper, C.; Mundt, P.; Berg, E.; Giese, T.; Stallmach, A.; Zeitz, M.; Duchmann, R. Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology 2005, 128, 1868-1878.
142. McIntyre, T.M.; Strober, W. Gut-associated Lymphoid Tissue. Regulation of IgA B-cell Development. In Mucosal Immunology; Ogra, L.P., Mestecky, J., Lamm, M.E., Strober, W., Bienenstock, J., McGhee, J.R., Eds.; Academic Press: New York, NY, USA, 1999; pp. 319-356.
143. Benson, E.B.; Strober, W. Regulation of IgA secretion by T cell clones derived from the human gastrointestinal tract. J. Immunol. 1988, 140, 1874-1882.
144. Ogata, K.; An, E.; Shioi, Y.; Nakamura, K.; Luo, S.; Yokose, N.; Minami, S.; Dan, K. Association between natural killer cell activity and infection in immunologically normal elderly people. Clin. Exp. Immunol. 2001, 124, 392-397.
145. Penders, J.; Thijs, C.; van den Brandt, P.A.; Kummeling, I.; Snijders, B.; Stelma, F.; Adams, H.; van Ree, R.; Stobberingh, E.E.; Gut microbiota composition and development of atopic manifestations in infancy: The KOALA Birth Cohort Study. Gut 2007, 56, 661-667.
146. Wang, M.; Karlsson, C.; Olsson, C.; Adlerberth, I.; Wold, A.; Strachan, D.P.; Martricardi, P.M.; Åberg, N.; Perkin, M.R.; Tripodi, S. et al.; Reduced diversity in the early fecal microbiota of infants with atopic eczema. J. Allergy Clin. Immunol. 2008, 121, 129-134.
147. Saarinen, K.M.; Sarnesto, A.; Savilahti, E. Markers of inflammation in the feces of infants with cow's milk allergy. Pediatr. Allergy Immunol. 2002, 13, 188-194.
148. Majamaa, H.; Miettinen, A.; Laine, S.; Isolauri, E. Intestinal inflammation in children with atopic eczema: Faecal eosinophil cationic protein and tumour necrosis factor-alpha as non-invasive indicators of food allergy. Clin. Exp. Allergy 1996, 26, 181-187.
149. Ahrne, S.; Johansson Hagslatt, M.-L. Effect of lactobacilli on paracellular permeability in the gut. Nutrients 2011, 3, 104-117.
150. Backhed, F.; Ding, H.; Wang, T.; Hooper, L.V.; Koh, G.Y.; Nagy, A.; Semenkovich, C.F.; Gordon, J.I. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA 2004, 101, 15718-15723.
151. Ley, R.E.; Turnbaugh, P.J.; Klein, S.; Gordon, J.I. Microbial ecology: Human gut microbes associated with obesity. Nature 2006, 444, 1022-1023.
152. Raoult, D.; Obesity pandemics and the modification of digestive bacterial flora. Eur. J. Clin. Microbiol. Infect. Dis. 2008, 27, 631-634.
153. Raoult, D.; Probiotics and obesity: A link? Nat. Rev. Microbiol. 2009, 7, 616; doi:10.1038/nrmicro2209.
154. Ehrlich, S.D.; Probiotics-little evidence for a link to obesity. Nat. Rev. Microbiol. 2009, 7, 901; doi:10.1038/nrmicro2209-c1.
155. Delzenne, N.; Reid, G.; No causal link between obesity and probiotics. Nat. Rev. Microbiol. 2009, 7, 901; doi:10.1038/nrmicro2209-c2.
156. Kannel, W.B.; Wolf, P.A.; Castelli, W.P.; D'Agnostino, R.B.; Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987, 258, 1183-1186.
157. Church, D.F.; Pryor, W.A.; Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect. 1985, 64, 111-126.
158. Tappia, P.S.; Troughton, K.L.; Langley-Evans, S.; Grimble, R.F.; Cigarette smoking influences cytokine production and antioxidant defences. Clin. Sci. 1995, 88, 485-489.
159. Goodwin, J.S.; Decreased immunity and increased morbidity in the elderly. Nutr. Rev. 1995, 53, S41-S44.
160. Kalache, A.; Active ageing makes the difference. Bull. World Health Organ. 1999, 77, 299.
161. Guigoz, Y.; Doré, J.; Schiffrin, E.J. The inflammatory status of old age can be nurtured from the intestinal environment. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11, 13-20.
162. Mikelsaar, M.; Stsepetova, J.; Hütt, P.; Kolk, H.; Sepp, E.; Lõivukene, K.; Zilmer, K.; Zilmer, M. Intestinal Lactobacillus sp. is associated with some cellular and metabolic characteristics of blood in elderly people. Anaerobe 2010, 16, 240-246.
163. Zeuzem, S.; Gut-liver axis. Int. J. Colorectal Dis. 2000, 15, 59-82.
164. Berg, R.D.; Garlinton, A.W.; Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect. Immun. 1979, 23, 403-411.
165. Jacob, A.I.; Goldberg, P.H.; Bloom, D.; Degenshein, G.A.; Korin, P.J. Endotoxin and bacteria in portal blood. Gastroenterology 1977, 72, 1268-1270.
166. Nolan, J.P.; Endotoxin, reticuloendothelial function and liver injury. Hepatology 1981, 1, 458-465.
167. Mathison, J.C.; Ulevitch, R.J.; The clearance, tissue distribution and cellular localization of intravenously injected lipopolysaccharide in rabbits. J. Immunol. 1979, 123, 2133-2143.
168. Ruiter, D.J.; van der Meulen, J.; Brouwer, A.; Hummel, M.J.; Mauw, B.J.; van der Ploeg, J.C.; Wisse, E. Uptake by liver cells of endotoxin following its intravenous injection. Lab. Invest. 1981, 45, 38-45.
169. Ishibashi, H.; Nakamura, M.; Komori, A.; Migita, K.; Shimoda, S.; Liver architecture, cell function, and disease. Semin. Immunopathol. 2009, 31, 399-409.
170. Racanelli, V.; Rehermann, B. The liver as an immunological organ. Hepatology 2006, 43, 54-62.
171. Van Leeuwen, P.A.; Boermeester, M.A.; Houdijk, A.P.; Ferwerda, C.C.; Cuesta, M.A.; Meyer, S.; Wesdorp, R.I. Clinical significance of translocation. Gut 1994, 35, 28-34.
172. Akira, S.; Takeda, K.; Kaisho, T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2, 675-680.
173. Mencin, A.; Kluwe, J.; Schwabe, R.F. Toll-like receptors as targets in chronic liver diseases. Gut 2009, 58, 704-720.
174. Szabo, G.; Bala, S.; Alcoholic liver disease and the gut-liver axis. World J. Gastroenterol. 2010, 16, 1321-1329.
175. Bataller, R.; Brenner, D.A. Liver fibrosis. J. Clin. Invest. 2005, 115, 209-218.
176. Seki, E.; De Minicis, S.; Osterreicher, C.H.; Kluwe, J.; Osawa, Y.; Brenner, D.A.; Schwabe, R.F.; TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007, 13, 1324-1332.
177. Lockwood, A.H.; Yap, E.W.; Wong, W.H.; Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J. Cereb. Blood Flow Metab. 1991, 11, 337-341.
178. Cordoba, J.; Alonso, J.; Rovira, A.; Jacas, C.; Sanpedro, F.; Castells, L.; Vargas, V.; Margarit, C.; Kulisewsky, J.; Esteban, R. et al.; The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J. Hepatol. 2001, 35, 598-604.
179. Stewart, S.; Jones, D.; Day, C.P. Alcoholic liver disease: New insights into mechanisms and preventative strategies. Trends Mol. Med. 2001, 7, 408-413.
180. Morgan, T.R.; Mandayam, S.; Jamal, M.M. Alcohol and hepatocellular carcinoma. Gastroenterology 2004, 127, S87-S96.
181. Apte, U.M.; Banerjee, A.; McRee, R.; Wellberg, E.; Ramaiah, S.K. Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis. Toxicol. Appl. Pharmacol. 2005, 207, 25-38.
182. Ramaiah, S.K.; Jaeschke, H. Hepatic neutrophil infiltration in the pathogenesis of alcohol-induced liver injury. Toxicol. Mech. Methods 2007, 17, 431-440.
183. McClain, C.J.; Barve, S.; Deaciuc, I.; Kugelmas, M.; Hill, D. Cytokines in alcoholic liver disease. Semin. Liver Dis. 1999, 19, 205-220.
184. Such, J.; Guardiola, J.V.; de Juan, J.; Casellas, J.A.; Pascual, S.; Aparicio, J.R.; Solá-Vera, J.; Pérez-Mateo, M. Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis. Eur. J. Gastroenterol. Hepatol. 2002, 14, 371-376.
185. Zuckerman, M.J.; Menzies, I.S.; Ho, H.; Gregory, G.G.; Casner, N.A.; Crane, R.S.; Hernandez, J.A.; Assessment of intestinal permeability and absorption in cirrhotic patients with ascites using combined sugar probes. Dig. Dis. Sci. 2004, 49, 621-626.
186. Rao, R.K.; Seth, A.; Sheth, P.; Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxiemia in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G881-G884.
187. Xu, W.H.; Wu, X.J.; Li, J.S. Influence of portal pressure change on intestinal permeability in patients with portal hypertension. Hepatobiliary Pancreat. Dis. Int. 2002, 1, 510-514.
188. Medina, J.; Fernández-Salazar, L.I.; García-Buey, L.; Moreno-Otero, R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004, 27, 2057-2066.
189. Younossi, Z.M.; Diehl, A.M.; Ong, J.P. Nonalcoholic fatty liver disease: An agenda for clinical research. Hepatology 2002, 35, 746-752.
190. Lirussi, F.; Mastropasqua, E.; Orando, S.; Orlando, R.; Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 2007, CD005165; doi:10.1002/ 14651858.CD005165.pub2.
191. Hwang, S.T.; Cho, Y.K.; Park, J.H.; Kim, H.J.; Park, D.I.; Sohn, C.I.; Jeon, W.K.; Kim, B.I.; Won, K.H.; Jin, W. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J. Gastroenterol. Hepatol. 2010, 25, 562-567.
192. Farrell, G.C. Is bacterial ash the flash that ignites NASH? Gut 2001, 48, 148-149.
193. Nair, S.; Cope, K.; Risby, T.H.; Diehl, A.M.; Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001, 96, 1200-1204.
194. Wigg, A.J.; Roberts-Thomson, I.C.; Dymock, R.B.; McCarthy, P.J.; Grose, R.H.; Cummins, A.G. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48, 206-211.
195. Pessayre, D.; Mansouri, A.; Fromenty, B.; Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282, G193-G199.
196. Neuman, M.G.; Immune dysfunction in inflammatory bowel disease. Transl. Res. 2007, 149, 173-186.
197. Asakura, H.; Suzuki, A.; Ohtsuka, K.; Hasegawa, K.; Sugimura, K. Gut-associated lymphoid tissues in ulcerative colitis. J. Parenter. Enteral. Nutr. 1999, 23, 25-28.
198. Sasakawa, T.; Takizawa, H.; Bannai, H.; Narisawa, R.; Asakura, H. Activated CD4+ and CD8+ cells in the colonic mucosa of ulcerative colitis patients: their relationship to HLA-DR antigen expression on the colonic epithelium and serum soluble CD25 levels. Digestion 1995, 56, 516-522.
199. Blumberg, R.S.; Inflammation in the intestinal tract: Pathogenesis and treatment. Dig. Dis. 2009, 27, 455-464.
200. Dharmani, P.; Chadee, K. Biologic therapies against inflammatory bowel disease: A dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Curr. Mol. Pharmacol. 2008, 1, 195-212.
201. Abreu, M.T.; Arnold, E.T.; Thomas, L.S.; Gonsky, R.; Zhou, Y.; Hu, B.; Arditi, M. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J. Biol. Chem. 2002, 277, 20431-20437.
202. Cario, E.; Podolsky D.K.; Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 2000, 68, 7010-7017.
203. Baumgart, D.C.; Thomas, S.; Przesdzing, I.; Metzke, D.; Bielecki, C.; Lehmann, S.M.; Lehnardt, S.; Dörffel, Y.; Sturm, A.; Scheffold, A. et al.; Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin. Exp. Immunol. 2009, 157, 423-436.
204. Kanai, K.; Watanabe, M. Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel disease. Expert. Opin. Biol. Ther. 2005, 5, 451-462.
205. Pullan, R.D.; Thomas, G.A.O.; Rhodes, M.; Newcombe, R.G.; Williams, G.T.; Allen, A.; Rhodes, J. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994, 35, 353-359.
206. Corfield, A.P.; Myerscough, N.; Bradfield, N.; Corfield, C.D.A.; Gough, M.; Clamp, J.R.; Durdey, P.; Warren, B.F.; Bartolo, D.C.C.; King, K.R. et al.; Colonic mucins in ulcerative colitis: Evidence for loss of sulphation. Glycoconj. J. 1996, 13, 809-822.
207. Nishikawa, J.; Kudo, T.; Sakata, S.; Benno, Y.; Sugiyama, T. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand. J. Gastroenterol. 2009, 44, 180-186.
208. Kotlowski, R.; Bernstein, C.N.; Sepehri, S.; Krause, D.O. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 2007, 56, 669-675.
209. Rowan, F.E.; Docherty, N.G.; Coffey, J.C.; O'Connell, P.R.; Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br. J. Surg. 2009, 96, 151-158.
210. Pitcher, M.C.; Beatty, E.R.; Cummings, J.H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000, 46, 64-72.
211. Fabia, R.; Ar'Rajab, A.; Johansson, M.L.; Andersson, R.; Willén, R.; Jeppsson, B.; Molin, G.; Bengmark, S. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion 1993, 54, 248-255.
212. Andoh, A.; Sakata, S.; Koizumi, Y.; Mitsuyama, K.; Fujiyama, Y.; Benno, Y. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis. Inflamm. Bowel. Dis. 2007, 13, 955-962.
213. Zoetendal, E.G.; von Wright, A.; Vilpponen-Salmela, T.; Ben-Amor, K.; Akkermans, A.D.; de Vos, W.M.; Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 2002, 68, 3401-3407.
214. Zhang, M.; Liu, B.; Zhang, Y.; Wei, H.; Lei, Y.; Zhao, L. Structural shifts of mucosa-associated lactobacilli and Clostridium leptum subgroup in patients with ulcerative colitis. J. Clin. Microbiol. 2007, 45, 496-500.
215. Sang, L.X.; Chang, B.; Zhang, W.L.; Wu, X.M.; Li, X.H.; Jiang, M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J. Gastroenterol. 2010, 16, 1908-1915.
216. Sandborn, W.J. Pouchitis following ileal pouch-anal anastomosis: Definition, pathogenesis, and treatment. Gastroenterology 1994, 107, 1856-1860.
217. Elahi, B.; Nikfar, S.; Derakhshani, S.; Vafaie, M.; Abdollahi, M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials. Dig. Dis. Sci. 2008, 53, 1278-1284.
218. Kuhbacher, T.; Ott, S.J.; Helwig, U.; Mimura, T.; Rizzello, F.; Kleessen, B.; Gionchetti, P.; Blaut, M.; Campieri, M.; Fölsch, U.R. et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006, 55, 833-841.
219. Williams, S.M.; Harned, R.K. Hepatobiliary complications of inflammatory bowel disease. Radiol. Clin. North Am. 1987, 25, 175-188.
220. Masubuchi, Y.; Horie, T. Endotoxin-mediated disturbance of hepatic cytochrome P450 function and development of endotoxin tolerance in the rat model of dextran sulfate sodium-induced experimental colitis. Drug Metab. Dispos. 2004, 32, 437-441.
221. Rutter, M.; Saunders, B.; Wilkins, K.; Rumbles, S.; Schofield, G.; Kamm, M.; Williams, C.; Price, A.; Talbot, I.; Forbes, A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126, 451-459.
222. Gianotti, L.; Morelli, L.; Galbiati, F.; Rocchetti, S.; Coppola, S.; Beneduce, A.; Gilardini, C.; Zonenschain, D.; Nespoli, A.; Braga, M. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J. Gastroenterol. 2010, 16, 167-175.
223. Podolsky, D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347, 417-429.
224. Kornbluth, A.; Sacher, D.B. Ulcerative colitis practice guidelines in adults. Am. J. Gastroenterol. 2004, 99, 1371-1385.
225. Friedman, S.; Blumberg, R. Inflammatory Bowel Disease. In Harrison's Principles of Internal Medicine, 17th ed.; Fauci, A.S., Braunwald, E., Kasper, D.L., Hauser, S.L., Longo, D.L., Jameson, J.L., Loscalzo, J., Eds.; McGraw-Hill Companies: New York, NY, USA, 2008; pp. 1777-1789.
226. Ott, S.J.; Musfeldt, M.; Wenderoth, D.F.; Hampe, J.; Brant, O.; Fölsch, U.R.; Timmis, K.N.; Schreiber, S. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53, 685-693.
227. Swidsinski, A.; Ladhoff, A.; Pernthaler, A.; Swidsinski, S.; Loening-Baucke, V.; Ortner, M.; Weber, J.; Hoffmann, U.; Schreiber, S.; Dietel, M. et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002, 122, 44-54.
228. Butterworth, A.D.; Thomas, A.G.; Akobeng, A.K. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2008, CD006634; doi:10.1002/14651858. CD006634.pub2.
229. Weiss, J.F. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ. Health Perspect. 1997, 105, 1473-1478.
230. Weiss, J.F.; Landauer, M.R. Radioprotection by antioxidants. Ann. N. Y. Acad. Sci. 2000, 899, 44-60.
231. Berthrong, M. Pathologic changes secondary to radiation. World J. Surg. 1986, 10, 155-170.
232. Bismar, M.M.; Sinicrope, F.A. Radiation enteritis. Curr. Gastroenterol. Rep. 2002, 4, 361-365.
233. Molla, M.; Gironella, M.; Salas, A.; Miquel, R.; Pérez-del-Pulgar, S.; Conill, C.; Engel, P.; Biete, A.; Piqué, J.M.; Panés, J. Role of P-selectin in radiation-induced intestinal inflammatory damage. Int. J. Cancer 2001, 96, 99-109.
234. Novak, J.M.; Collins, J.T.; Donowitz, M.; Farman, J.; Sheahan, D.G.; Spiro, H.M. Effects of radiation on the human gastrointestinal tract. J. Clin. Gastroenterol. 1979, 1, 9-39.
235. Summers, R.W.; Flatt, A.J.; Prihoda, M.J.; Mitros, F.A. Effect of irradiation on morphology and motility of canine small intestine. Dig. Dis. Sci. 1987, 32, 1402-1410.
236. Fernandez-Banares, F.; Villa, S.; Esteve, M.; Roca, M.; Cabré, E.; Abad-Lacruz, A.; Martín-Comín, J.; Gassull, M.A. Acute effects of abdominopelvic irradiation on the orocecal transit time: Its relation to clinical symptoms, and bile salt and lactose malabsorption. Am. J. Gastroenterol. 1991, 86, 1771-1777.
237. Yeoh, E.K.; Horowit, M.; Russo, A.; Muecke, T.; Robb, T.; Chatterton, B.E. Gastrointestinal function in chronic radiation enteritis-effects of loperamide-N-oxide. Gut 1993, 34, 476-482.
238. Indaram, A.V.; Visvalingam, V.; Locke, M.; Bank, S. Mucosal cytokine production in radiation induced proctosigmoiditis compared with inflammatory bowel disease. Am. J. Gastroenterol. 2000, 95, 1221-1225.
239. Mikelsaar, M.; Türi, M.; Lencner, H.; Kolts, K.; Kirch, R.; Lencner, A. Interrelations between mucosal and luminal microflora of gastrointestine. Nahrung 1987, 31, 449-456, 637-638.
240. Deitch, E.A. The role of bacterial failure and bacterial translocation in the development of systemic infection and multiple organ failure. Arch. Surg. 1990, 125, 403-404.